3SBio

hot
Biotech

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific

Pfizer has bagged ex-China rights, establishing itself as a challenger to BioNTech, Merck and Summit in a scorching-hot area of immuno-oncology.
Nick Paul Taylor May 20, 2025 4:47am
Swiss flag by a lake

Vasella helps Numab to CHF22M round ahead of cancer trial start

Mar 9, 2020 7:00am
George Golumbeski

Verseau bags $50M for cancer R&D, names Golumbeski as chairman

Oct 21, 2019 12:05am
money

Refuge Biotech scores $25M from Chinese backers for CAR-T

May 2, 2018 10:49am